Read the full study results here.
The study registered 464 adults at 39 health centers. More than 80 percent of patients had actually already developed their own antibodies against COVID-19 by the time they got the convalescent plasma, which recommends they had contracted the virus a week or more prior to they received the treatment, STAT reported..
© Copyright ASC COMMUNICATIONS 2020. Intrigued in LINKING to or REPRINTING this content? View our policies by clicking here.
” I do not know whether it suffices to lead the FDA to withdraw its permission for this, but it certainly recommends its not the lifesaver that individuals thought it would be,” Susan Ellenberg, PhD, professor of biostatistics in and public health at the Hospital of the University of Pennsylvania in Philadelphia, told STAT..
Maia Anderson –
Friday, October 23rd, 2020
© Copyright ASC COMMUNICATIONS 2020. Intrigued in LINKING to or REPRINTING this content? View our policies by click on this link.
More articles on drug store: Remdesivir ends up being first FDA-approved COVID-19 treatment8 current legal actions involving pharmacists, drugmakersA breakdown of the 4 COVID-19 vaccine trials in late-stage testing.
Convalescent plasma drawn from COVID-19 survivors in India had no benefit for COVID-19 clients in a scientific trial, according to study outcomes released Oct. 22 in The BMJ..
The trial found that the treatment didnt affect whether COVID-19 clients got sicker or passed away. An earlier analysis from Rochester, Minn.-based Mayo Clinic had revealed it did have some benefit, which prompted the FDA to approve it emergency usage permission in August, but that study didnt have a control arm, STAT reported..
Arturo Casadevall, MD, PhD, a transmittable disease specialist at the Johns Hopkins Bloomberg School of Public Health in Baltimore, told STAT the research study was inconclusive because researchers currently knew convalescent plasma needs to be offered previously on o advantage patients..